GlassScriptPhysician profile
Janet Cooper
NPI 1982761912
$1,967.86
in general payments reported to CMS, 2019-2025
34 companies · $635 in 2025
The $635 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.56 · 2021: $665 · 2022: $329 · 2023: $313 · 2024: $13.56 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $242.74 | 2023 | Xpovio |
| Incyte Corporation | $159.05 | 2021-2025 | Monjuvi, Zynyz |
| Janssen Biotech, INC. | $154.54 | 2021-2025 | Rybrevant, Erleada, Balversa |
| E.R. Squibb & Sons, L.L.C. | $139.51 | 2021 | |
| Merck Sharp & Dohme LLC | $117.77 | 2021-2025 | Lynparza, Keytruda |
| Amgen INC. | $116.73 | 2021-2022 | |
| Daiichi Sankyo INC. | $111.23 | 2021-2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $82.27 | 2021-2025 | Iclusig |
| Beigene USA, INC. | $69.94 | 2023 | Brukinsa |
| Coherus Oncology, INC. | $65.44 | 2021-2025 | Loqtorzi |
| Astrazeneca Pharmaceuticals LP | $50.32 | 2021-2025 | Calquence |
| Glaxosmithkline, LLC. | $43.75 | 2021 | |
| Novartis Pharmaceuticals Corporation | $43.01 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $42.50 | 2022-2025 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.65 | 2021-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $40.11 | 2021-2025 | Optune Gio |
| Pfizer INC. | $38.80 | 2025 | |
| Tempus Ai, INC | $38.60 | 2025 | Xt Cdx |
| Eisai INC. | $36.72 | 2022-2025 | |
| Genentech USA, INC. | $35.63 | 2025 | Polivy, Phesgo |
| Genzyme Corporation | $29.51 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $28.46 | 2021-2022 | |
| Immunocore Limited | $26.87 | 2025 | Kimmtrak |
| Seagen INC. | $26.47 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.92 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $24.32 | 2019-2022 | |
| Servier Pharmaceuticals LLC | $22.13 | 2025 | |
| Alexion Pharmaceuticals, INC. | $21.94 | 2022 | |
| Beone Medicines USA, INC. | $20.22 | 2025 | Tevimbra |
| Emd Serono, INC. | $18.21 | 2025 | |
| Dova Pharmaceuticals | $15.04 | 2021 | |
| Astellas Pharma US INC | $14.46 | 2022 | |
| Pharmaand Gmbh | $13.24 | 2025 | Rubraca |
| Array Biopharma INC | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.